The venture capital in the biotechnology industry

The Biotechnology investment sector has been booming over the last ten years delivering substantial financial returns for public and private investors and most VC firms have been raising and deploying a lot of capital into fast-growing Biotechnology companies. However, it may seem paradoxical that the Biotechnology industry attracts increasingly more Venture Capital and Public funding whereas it is one of the riskiest and volatile sectors and most early-stage companies do not generate revenues for years and have large financial needs to cover expensive clinical trials. My research will focus on Biotechnology investments in the US and will cover the value chain of a Venture Capital firm with a competitive analysis, a detailed review of current funding trends, a performance review analysis and a study to explain why Boston has become the n°1 cluster for Biotechnology in the US. The study also includes feedbacks from 25 interviews conducted with Founders and CEOs of Biotechnology companies, Life Sciences experts, Scientists and Venture Capital investors.

Department dc:contributor.department

Sloan School of Management.

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2016

Author dc:creator

• Grislain, Jacques-Henry

Advisor dc:contributor.advisor

• Robert S. Langer.

• Sloan School of Management.

Statement dc:rights

• M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/1721.1/104535

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/104535